Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
206.20 USD   +0.97%
05/27BIOGEN : to Participate in the Jefferies Healthcare Conference
PU
05/23MARKETSCREENER'S WORLD PRESS REVIEW : May 23, 2022
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen on Cusp of 'Change' in Wedbush View as Medicare's Proposed Plan for Alzheimer's Drug Coverage Likely Limits its Use

01/18/2022 | 06:07am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about BIOGEN INC.
05/27BIOGEN : to Participate in the Jefferies Healthcare Conference
PU
05/23MARKETSCREENER'S WORLD PRESS REVIEW : May 23, 2022
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D..
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of..
CI
05/05Japanese shares rise on energy, financials boost
RE
05/05Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait ..
MT
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 9 838 M - -
Net income 2022 1 996 M - -
Net cash 2022 60,0 M - -
P/E ratio 2022 14,7x
Yield 2022 -
Capitalization 30 198 M 30 198 M -
EV / Sales 2022 3,06x
EV / Sales 2023 2,87x
Nbr of Employees 9 610
Free-Float 85,4%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Last Close Price 206,20 $
Average target price 245,86 $
Spread / Average Target 19,2%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-14.05%30 198
CSL LIMITED-7.17%92 708
SAMSUNG BIOLOGICS CO.,LTD.-7.64%47 463
WUXI BIOLOGICS (CAYMAN) INC.-45.27%29 183
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-32.02%20 229
UCB-17.47%16 785